Method and compositions for altering mucus secretion

Details Method and compositions for altering mucus secretion Method and compositions for altering mucus secretion

2007-09-04

2007-09-04

Epps-Ford, Janet (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S013800, C514S014800, C514S015800

Reexamination Certificate

active

09914020

ABSTRACT:
Methods and compounds for increasing or decreasing mucus secretion in subjects, and particularly mucus secretion in the airways, are described. Methods of screening compounds for the ability to increase or decrease mucus secretion are also described.

REFERENCES:
patent: 4753945 (1988-06-01), Gilbard et al.
patent: 4873346 (1989-10-01), Anderson
patent: 5298506 (1994-03-01), Stamler et al.
patent: 5436243 (1995-07-01), Sachs et al.
patent: 5849706 (1998-12-01), Molina y Vedia et al.
patent: 5849719 (1998-12-01), Carson et al.
patent: 5858784 (1999-01-01), Debs et al.
patent: 5858981 (1999-01-01), Schreiber et al.
patent: 5861502 (1999-01-01), Prockop et al.
patent: 0551200 (1993-07-01), None
patent: WO93/00353 (1993-01-01), None
patent: WO95/27496 (1995-10-01), None
patent: WO96/18103 (1996-06-01), None
Rogers, Duncan. Mucus hypersecretion in chronic obstructive pulmonary disease. Chronic Obstructive Pulmonary Disease: Pathogenesis to Treatment: Novartis Foundation. Symposium 234. vol. 234. Copyright © Novartis Foundation. 2001. ISBN:0-471-49437-2.
Barnes, Peter J. Current and Future therapeies for airway mucus hypersecretion. Novartis Foundation Symposium, vol. 248. Copyright © Novartis Foundation, 2002. ISBN: 0-470-84478-7, pp. 237-253.
Rogers, Duncan F. (2003) Pulmonary Mucus: Pediatric Perspective. Pediatric Pulmonology, vol. 36: 178-188.
Ward et al. 1994, Therapeutic Immunology. vol. 1, pp. 165-171.
Singer et al.,A MARCKS-related peptide blocks mucus hypersecretion in a mouse model of asthma, Nature Medicine, vol. 10, No. 2, Feb. 2004, pp. 193-196.
International Search Report, PCT/US00/05050, Sep. 29, 2000.
Adler et al.,Myristoylated Alanine-Rich C-Kinase Substrate Protein: A Major Intracellular Regulatory Molecule Controlling Secretion of Mucin by Human Airway Goblet Cells, Chest, vol. 117, 2000, pp. 266S-267S.
Adler et al.,Effects of Inflammatory Mediators and Drugs on Mucus Secretion and Mucociliary Function, Research in Immunology, vol. 149, 1998 pp. 245-248.
Lu et al.,Regulation of Angiotensin II-Induced Neuromodulation by MARCKS in Brain Neurons, The Journal of Cell Biology, vol. 142, No. 1, Jul. 13, 1998, pp. 217-227.
Nakamura et al.,Mucin-Like Glycoprotein Secretion is Mediated by Cyclic-AMP and Protein Kinase C Signal Transduction Pathways in Rat Corneal Epithelium, Experimental Eye Research, vol. 66, 1998, pp. 513-519.
Myat et al.,Identification of the Basolateral Targeting Determinant of a Peripheral Membrane Protein, MacMARCKS, in Polarized Cells, Current Biology, vol. 8, 1998, pp. 677-683.
Gipson et al., Abstract ofCellular Origin of Mucins of the Ocular Surface Tear Film, Adv. Exp. Med. Biol., vol. 438, 1998, pp. 221-227.
Garcher et al., Abstract ofCA 19-9 ELISA Test: A New Method for Studying Mucus Changes in Tears, Br. J. Ophthalmol., vol. 82, No. 1, Jan. 1998, pp. 88-90.
Dray-Charier et al.,Regulation of Mucin Secretion in Human Gallbladder Epithelial Cells: Predominant Role of Calcium and Protein Kinase C, Gastroenterology, vol. 112, 1997, pp. 978-990.
Raufman et al,Expression and Phosphorylation of a MARCKS-Like Protein in Gastric Chief Cells: Further Evidence for Modulation of Pepsinogen Secretion by Interaction of Ca2+/Calmodulin With Protein Kinase C, Journal of Cellular Biochemistry, vol. 64, 1997, pp. 514-523.
Ko et al.,ATP-Induced Mucin Release From Cultured Airway Goblet Cells Involves, in Part, Actvation of Protein Kinase C, Am. J. Respir. Cell Mol. Biol., vol. 16, 1997, pp. 194-198.
Abdullah et al.,Protein Kinase C and Ca2+Activation of Mucin Secretion in Airway Goblet Cells, American Journal of Physiology, 273 (Lung Cellular and Molecular Physiology 17), 1997, pp. L201-L210.
Mastropasqua et al., Abstract ofTear Deficiency in Fuchs' Intermediate Uveitis, Can. J. Ophthalmol., vol. 31, No. 1, Feb. 1996, pp. 18-20.
Adler et al.,Hypersection of Mucin in Response to Inflammatory Mediators by Guinea Pig Tracheal Epithelial Cells In Vitro Is Blocked by Inhibition of Nitric Oxide Synthase, Am. J. Respir. Cell Mol. Biol., vol. 13, 1995, pp. 526-530.
Aderem,The MARCKS Family of Protein Kinase-C Substrates, Biochemical Society Transactions, vol. 23, 1995, pp. 587-591.
Stormshak et al.,Dynamics of Molecular Mechanisms Underlying Ovarian Oxytocin Secretion, Journal of Reproduction and Fertility Supplement, vol. 49, 1995, pp. 379-390.
Kessler et al., Abstract ofStimulation of Goblet Cell Mucous Secretion by Activation of Nerves in Rat Conjunctiva, Curr. Eye Res., vol. 14, No. 11, Nov. 1995, pp. 985-992.
Vergéres et al.,The Myristoyl Moiety of Myristoylated Alanine-Rich C Kinase Susbtrate(MARCKS)and MARCKS-Related Protein Is Embedded in the Membrane, The Journal of Biological Chemistry, vol. 270, No. 34, Aug. 25, 1995, pp. 19879-19887.
Lui et al.,Arginine Vasopressin(AVP)Causes the Reversible Phosphorylation of the Myristoylated Alanine-Rich C Kinase Substrate(MARCKS)Protein in the Ovine Anterior Pituitary: Evidence That MARCKS Phosphorylation is Associated With Adrenocorticotropin(ACTH)Secretion, Molecular and Cellular Endocrinology, vol. 105, 1994, pp. 217-226.
Coffey et al.,Glutamate Exocytosis and MARCKS Phosphorylation are Enhanced by a Metabotropic Glutamate Receptor Coupled to a Protein Kinase C. Synergistically Activated by Diacylglycerol and Arachidonic Acid, Journal of Neurochemistry, vol. 63, No. 4, 1994, pp. 1303-1310.
Liu et al.,Arginine Vasopressin(AVP)Causes the Reversible Phosphorylation of the Myristoylated Alanine-Rich C Kinase Substrate(MARCKS)Protein in the Ovine Anterior Pituitary: Evidence That MARCKS Phosphorylation is Associated With Adrenocorticotropin(ACTH)Secretion, Molecular and Cellular Endocrinology, vol. 101, 1994, pp. 247-256.
Aigner et al.,Depletion of 43-kD Growth-Associated Protein in Primary Sensory Neurons Leads to Diminished Formation and Spreading of Growth Cones, The Journal of Cell Biology, vol. 123, No. 2, Oct. 1993, pp. 417-429.
Calle et al.,Glucose-Induced Phosphorylation of Myristoylated Alanine-Rich C Kinase Substrate(MARCKS)in Isolated Rat Pancreatic Islets, The Journal of Biological Chemistry, vol. 267, No. 26, Sep. 15, 1992, pp. 18723-18727.
Driot et al., Abstract ofBeneficial Effects of a Retinoic Acid Analog, CBS-211 A, On An Experimetal Model of Keratoconjunctivitis Sicca., Invest. Ophthalmol. Vis. Sci., vol. 33, No. 1, Jan. 1992, pp. 190-195.
Graff et al.,Protein Kinase C Susbtrate and Inhibitor Characteristics of Peptides Derived From the Myristoylated Alanine-Rich C Kinase Substrate(MARCKS)Protein Phosphorylation Site Domain, The Journal of Biological Chemistry, vol. 266, No. 22, Aug. 5, 1991, pp. 14390-14398.
Harlan et al.,The Human Myristoylated Alanine-Rich C Kinase Substrate(MARCKS)Gene(MACS), The Journal of Biological Chemistry, vol. 266, No. 22, Aug. 5, 1991, pp. 14399-14405.
Thelen et al.,Regulation by Phosphorylation of Reversible Association of a Myristoylated Protein Kinase C Susbtrate with the Plasma Membrane, Nature, vol. 351, May 23, 1991, pp. 320-322.
Thelen et al.,Tumor Necrosis Factor α Modifies Agonist-Dependent Responses in Human Neutrophils by Inducing the Synthesis and Myristoylation of a Specific Protein Kinase C Substrate, Proc. Natl. Acad. Sci., USA, vol. 87, Aug. 1990, pp. 5603-5607.
Linsen et al., Abstract ofPhysiology of the Lacrimal System, Bull Soc. Belge Ophtalmol., vol. 238, 1990, pp. 35-44.
Shellans et al., Abstract ofConjunctival Goblet Cell Response to Vasoconstrictor Use, J. Ocul. Pharmacol., vol. 5, No. 3, Fall 1989, pp. 217-220.
Stumpo et al.,Molecular Cloning, Characterization, and Expression of a cDNA Encoding the “80-to 87-kDa” Myristoylated Alanine-Rich C Kinase Substrate; A Major Cellular Substrate of Protein Kinase C, Proc. Natl. Acad. Sci., USA, vol. 86, 1989, pp. 4012-4016.
Aragona et al., Abstract ofEffects of a Stable Analogue of PGE2(11-deoxy-13, 14-didehydro-16(S)-Methylester Methyl PGE2: FCE 20700)on the Secretory Processes on Conjunctival Goblet Cells of Rabbit., Exp. Eye Res., vol. 45, No. 5, Nov. 1987, pp. 647-654.
Tseng, Abstract ofTopical Tretinoin Treatment for Severe Dry-Eye Disorders, J. Am. Acad. Dermatol., vol. 1

Affiliated with

Also associated with

Rating

Method and compositions for altering mucus secretion does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and compositions for altering mucus secretion, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for altering mucus secretion will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3744037